Breast Cancer, Version 1.2016.

This report summarizes these recent updates and discusses the rationale behind them. PMID: 26656517 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Related Links:

In this study, we highlighted mechanisms underlying the regulation of breast cancer molecular signatures by TFs and miRNAs which their alteration reduce the chance of survival rate in each subtype of breast cancer. Our current study in a holistic insight revealed the importance of some genes and their regulators as potential prognostic markers and/or therapeutic targets in breast cancer patients.
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Though current pathological methods are greatly improved, they provide rather limited functional information. Cell-in-cell structures (CICs), arising from active cell–cell interaction, are functional surrogates of complicated cell behaviors within heterogeneous cancers. In light of this, we performed the subtype-based CIC profiling in human breast cancers by the “EML” multiplex staining method, and accessed their values as prognostic factors by Cox univariate, multivariate, and nomogram analysis. CICs were detected in cancer specimens but not in normal breast tissues. A total of five types of CICs were id...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Metastatic Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: SHR6390;   Drug: Letrozole;   Drug: Capecitabine Sponsors:   Jinming Yu;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Positive Breast Cancer Intervention:   Drug: TCHP Sponsor:   Guangdong General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: SHR6390;   Drug: Letrozole;   Drug: Capecitabine Sponsors:   Jinming Yu;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Positive Breast Cancer Intervention:   Drug: TCHP Sponsor:   Guangdong General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: SHR6390;   Drug: Letrozole;   Drug: Capecitabine Sponsors:   Jinming Yu;   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Positive Breast Cancer Intervention:   Drug: TCHP Sponsor:   Guangdong General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ist S, Paluchoswski P, Wilke C, Heilenkötter U, Terracciano L, Müller V, Wilczak W, Burandt EC Abstract Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression in 2,197 breast cancers. LPCAT1 staining was found in 97.8% of 1,774 interpretable tumors, including 48.1% with weak, 28.7% with moderate, and 14.4% with strong expression. The frequency of LPCAT1 positivity depended on the histological tumor type. Moderate or strong LPCAT1 positivity was more com...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Women